|
|
|
| Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis |
| Jian-An Chen a , b , Yan Yu a , b , Chen Xue a , b , Xiao-Long Chen a , b , Guang-Ying Cui a , b , Juan Li a , b , Kong-Fei Li c , Zhi-Gang Ren a , b , Ran-Ran Sun a , b , ∗ |
a Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
b Key Laboratory of Clinical Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
c Department of Hematology, Yinzhou People’s Hospital Affiliated to Medical College of Ningbo University, Ningbo 315040, China
∗ Corresponding author at: Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
E-mail address: sunran1986318@163.com (R.-R. Sun). |
|
|
|
Abstract Background: microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors.
Data sources: PubMed, Web of Science and Embase databases were searched and publications from Jan- uary 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis.
Results: Eight individual studies from seven articles were included. Pooled analyses showed that low miR- 139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P < 0.001] in solid tumors, including hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM), consisting with the results of TCGA. However, our results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon; whereas for CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results. The results of 27 mi- croarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues com- pared to adjacent non-tumor tissues or healthy tissues. Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR = 3.57; 95% CI: 1.44–8.85; P = 0.006). However, the combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR = 1.50; 95% CI: 0.69–3.24; P = 0.304), gender (pooled OR = 0.92; 95% CI: 0.56–1.51; P = 0.738), tumor size (pooled OR = 1.51; 95% CI: 0.69–3.31; P = 0.298), late tumor-node-metastasis stage (pooled OR = 1.63; 95% CI: 0.99–2.68; P = 0.057) and lymph-node-metastasis (pooled OR = 0.66; 95% CI: 0.34–1.28; P = 0.222).
Conclusions: Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker. However, its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies.
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
